Table 5

Distribution of factors associated with anaemia among study participants
Frequency Multivariate analysis
Anaemic group (n=176) Non anaemic group (n=176) aOR (95%CI) p value
Variables
Gender
Female 69 (39.43%) 83 (47.16%) Reference
Male 106 (60.57) 93 (52.84%) 1.37 [0.82-2.31] 0.22
Age group
1year 57 (32.76%) 8 (4.55%) Reference
[2–4 years] 89 (51.15%) 73 (45.48%) 0.13 [0.05-0.31] 0.001
[5 – 10 years] 28 (16.09%) 95 (53.98) 0.03 [0.01-0.08] 0.001
Access to IPTc drug (SP-AQ)
No 87 (49.71%) 88 (50%) Reference
Yes 88 (50.29%) 88 (50%) 0.78 [0.45-1.33]
Stunting
No 84 (48%) 131 (74%) Reference
Yes 91 (52%) 45 (25.57%) 3.37 [1.93-5.88] 0.001
Malaria Parasitaemia
No 166 (94.86%) 174 (98.86%) Reference
Yes 9 (5.14%) 2 (1.14%) 5.23 [1.1-28.48] 0.04
Sickle cell disorders
No 145 (82.86%) 161 (91.48%) Reference
Yes 30 (17.14%) 15 (8.52%) 2.89 [1.32-6.34] 0.008
Alpha Thalassemia
No 128 (73.14%9 146 (82.95%) Reference
Yes 47 (28.86%) 30 (17.05%) 1.82 [1.2-3.35] 0.04

aOR: adjusted odds ratio. IPTc: Intermittent Preventive Treatment in children. SP-AQ: Sulfadoxine-Pyrimethamine. Goodness-of-fit-test: Hosmer-Lemeshow, Chi2 (8df)=5.07, p=0.75.

Tine et al.

Tine et al. BMC Research Notes 2012 5:565   doi:10.1186/1756-0500-5-565

Open Data